


LETTER TO THE EDITOR

Open Access



SELP Asp603Asn and severe thrombosis in COVID-19 males

Chiara Fallerini^{1,2}, Sergio Daga^{1,2}, Elisa Benetti², Nicola Picchiotti^{3,4}, Kristina Zguro², Francesca Catapano^{1,2}, Virginia Baroni^{1,2}, Simone Lanini⁵, Alessandro Bucalossi⁶, Giuseppe Marotta⁶, Francesca Colombo⁷, Margherita Baldassarri^{1,2}, Francesca Fava^{1,2,8}, Giada Beligni^{1,2}, Laura Di Sarno^{1,2}, Diana Alaverdian^{1,2}, Maria Palmieri^{1,2}, Susanna Croci^{1,2}, Andrea M. Isidori⁹, Simone Furini², Elisa Frullanti^{1,2} on behalf of GEN-COVID Multicenter Study, Alessandra Renieri^{1,2,8*}  and Francesca Mari^{1,2,8}

Abstract

Thromboembolism is a frequent cause of severity and mortality in COVID-19. However, the etiology of this phenomenon is not well understood. A cohort of 1186 subjects, from the GEN-COVID consortium, infected by SARS-CoV-2 with different severity was stratified by sex and adjusted by age. Then, common coding variants from whole exome sequencing were mined by LASSO logistic regression. The homozygosity of the cell adhesion molecule P-selectin gene (*SELP*) rs6127 (c.1807G > A; p.Asp603Asn) which has been already associated with thrombotic risk is found to be associated with severity in the male subcohort of 513 subjects (odds ratio = 2.27, 95% Confidence Interval 1.54–3.36). As the *SELP* gene is downregulated by testosterone, the odd ratio is increased in males older than 50 (OR 2.42, 95% CI 1.53–3.82). Asn/Asn homozygotes have increased D-dimers values especially when associated with poly Q \geq 23 in the androgen receptor (OR 3.26, 95% CI 1.41–7.52). These results provide a rationale for the repurposing of antibodies against P-selectin as adjuvant therapy in rs6127 male homozygotes especially if older than 50 or with an impaired androgen receptor.

Keywords: COVID-19, Thromboembolism, Thrombus, Venous thromboembolism, P-selectin, Anti-selectin P monoclonal antibodies

To the Editor

It is now widely recognized that COVID-19 is a systemic disease, characterized by dysregulation of the immune system and by a hypercoagulable state [1]. The bases of this prothrombotic susceptibility remain until now elusive, even if it is evident that host genetic factors largely contribute to COVID-19 phenotypic variability. Rare variants of genes involved in adaptive immunity have been identified in Mendelian forms of COVID-19, where the presence of one rare mutation leads to a severe

COVID-19 phenotype segregating in the family following a classic Mendelian inheritance pattern [2]. Among common genetic factors, the protective role of the 0 blood group has been identified, at least in part possibly due to von Willebrand factor (vWF) destabilization protecting from thrombosis [3]. We have also shown that longer polyQ repeats (\geq 23) in the androgen receptor (AR) predispose to severe COVID-19 outcome due to reduced testosterone anti-inflammatory and anti-thrombotic effect [4].


The P-selectin (*SELP*) gene encodes a cell adhesion molecule mediating the interaction of activated platelets on endothelium with leukocytes and playing a key role in thrombosis [5, 6]. Furthermore, significantly increased P-selectin and other prothrombotic biomarkers

*Correspondence: alessandra.renieri@unisi.it

¹ Medical Genetics Unit, University of Siena, Policlinico Le Scotte, Viale Bracci, 2, 53100 Siena, Italy

Full list of author information is available at the end of the article





concentration in plasma samples of severe COVID-19 patients compared to healthy controls has been recently reported [7, 8].

Among *SELP* variants, the Asp603Asn functional polymorphism (rs6127; c.1807G>A—previously reported as Asp562Asn or Asp541Asn) has been associated with thrombotic risk in various conditions [9, 10]. The

polymorphism, together with other coding polymorphisms, has indeed been shown to affect the binding of P-selectin to its ligand on leukocytes, possibly making the protein more efficient at recruiting leukocytes to the endothelium [10].

Within the Italian GEN-COVID cohort, we applied an ordered logistic regression to the clinical WHO gradings,

Table 1 Chi-square test in male cohort calculated for all ages (a); for age ≥ 50 years (b); and combination of AR poly-Q ≥ 23 and D-dimer value (c)

a	Severe (%)	Mild (%)	Marginal row totals
<i>Chi-square test in male cohort (all ages)</i>			
Asn/Asn genotype	90 (38.14)	59 (21.30)	149
Asp/Asp and Asp/Asn genotype	146 (61.86)	218 (78.70)	364
Marginal column totals	236 (100)	277 (100)	513 (grand total)
b	Severe (%)	Mild (%)	Marginal row totals
<i>Chi-square test in males ≥ 50 years</i>			
Asn/Asn genotype	73 (39.25)	40 (21.05)	113
Asp/Asp and Asp/Asn genotype	113 (60.75)	150 (78.95)	263
Marginal column totals	186 (100)	190 (100)	376 (grand total)
c	D-dimer > 5000	D-dimer < 5000	Marginal row totals
<i>Chi-square test of combination of AR poly Q ≥ 23 and D-dimer value</i>			
Asn/Asn and AR polyQ ≥ 23	10	19	29
Asp/Asp and Asp/Asn and AR polyQ < 23	40	248	288
Marginal Column totals	50	267	317 (grand total)
<i>p value (severe vs mild) = 2.8×10^{-5} (OR 2.27, 95% CI 1.54–3.36)</i>			
<i>p value (severe vs mild) = 1.19×10^{-4} (OR 2.42, 95% CI 1.53–3.82)</i>			
<i>p value (D-dimer > 5000 vs D-dimer < 5000) = 3.73×10^{-3} (OR 3.26, 95% CI 1.41–7.52)</i>			

stratified by sex and adjusted by age in order to define severe and mild patients (see Additional file 1: Supplementary file). We then tested by LASSO logistic regression different combinations of coding polymorphisms in homozygous state and found that the *SELP* rs6127 polymorphism correlates with severity only in the subcohort of males (Fig. 1a; Table 1a; Supplementary file; data on females not shown). The genotypic frequencies of the polymorphism in severe and mild patients were confirmed to be in Hardy–Weinberg equilibrium; the minor allele frequency in our cohort was similar to that reported in the European (non-Finnish) population in the gnomAD database (56.2% vs 55.8%) (<https://gnomad.broadinstitute.org/>).

The hyper-inflammatory and hyper-thrombotic state, due to viral injury of the vascular endothelium, leads to the release of P-selectin by activated platelets, driving thrombosis and vascular inflammation probably more efficiently in those individuals with enhanced P-selectin activities due a double copy of Asparagine 603 [10]. These results are in line with the demonstration that SARS-CoV-2 induces thrombosis by binding to ACE2 on platelets and subsequent integrin α IIb β 3 activation and P-selectin expression [11], and that P-selectin soluble isoform is increased in thrombosis [6] and severe COVID-19 [7, 8].

Since *SELP* transcription is inhibited by androgens [12], the strength of the association should increase with age. Interestingly, the OR (2.42) in males aged ≥ 50 years with respect to the whole cohort (OR = 2.27) is increased (Table 1).

In a subset of 52 severely affected hospitalised males, four main laboratory parameters related to a proinflammatory state (lymphocyte count, D-dimer and LDH) and a higher risk for thrombosis (D-dimer, platelet count and LDH) were longitudinally followed (Fig. 1b–e). We observed that the maximum pick (over 10 times of the normal upper value) was exclusive of Asp/Asn and Asn/Asn genotypes and older patients (Fig. 1b–e). The pick timing was earlier in Asn/Asn (median 7.5 days from infection) than Asp/Asn (median 13.5 days from infection), (p value = 3×10^{-2} , Fig. 1f). As the vWF is a downstream effector for clotting, the non-0 blood groups, associating with more stable vWF, also correlate with higher D-dimer and LDH values (Fig. 1g, h), in agreement with previous reports [3].

Given the stronger association of the *SELP* polymorphism in older males, the AR poly-Q status would impact on the *SELP* genotype [4]: the combination of poly-Q ≥ 23 with homozygous *SELP* polymorphism versus D-dimer value reached an OR of 3.26 (Table 1c). This result indicates that the two polymorphisms enhance each other, being two pieces of the same puzzle contributing to thrombosis in COVID-19 males.

Anti-*P-Selectin* monoclonal antibodies have been developed for human use: the phase-3 Inlacumab and the FDA&EMA approved Crizanlizumab, the latter as a prevention of vaso-occlusive crises in patients with sickle cell disease [13]. A general clinical trial to test the efficacy and safety of Crizanlizumab in not selected hospitalized COVID-19

patients is ongoing (<https://clinicaltrials.gov/ct2/show/study/NCT04435184>). Clinical trials in COVID-19 hospitalised males with *SELP* rs6127 should now be encouraged.

Abbreviations

AR: Androgen receptor; SELP: P-selectin gene; vWF: Von Willebrand factor.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s13045-021-01136-9>.

Additional file 1. Material and Methods plus study group appendix.

Acknowledgements

This study is part of the GEN-COVID Multicenter Study, <https://sites.google.com/dbm.unisi.it/gen-covid>, the Italian multicenter study aimed at identifying the COVID-19 host genetic bases. Specimens were provided by the COVID-19 Biobank of Siena, which is part of the Genetic Biobank of Siena, member of BBMRI-IT, of Telethon Network of Genetic Biobanks (project no. GTB18001), of EuroBioBank, and of RDConnect. We thank the CINECA consortium for providing computational resources and the Network for Italian Genomes (NIG) <http://www.nig.cineca.it> for its support. We thank private donors for the support provided to A.R. (Department of Medical Biotechnologies, University of Siena) for the COVID-19 host genetics research project (D.L n.18 of March 17, 2020).

Authors' contributions

AR, FM and EF designed the study; CF, SD, EB, NP, KZ, FC, VB, GB, LDS, DA, SL, SC, MP, AB, GM, AMI, EF, SF analyzed the data; EB, KZ, NP, SF performed statistical analysis; MB, FF and GEN-COVID Multicenter Study provided clinical data; AR and FM supervised the study. All authors read and approved the final manuscript.

Funding

We thank the COVID-19 Host Genetics Initiative (<https://www.covid19hg.org/>), MIUR project "Dipartimenti di Eccellenza 2018–2020" to the Department of Medical Biotechnologies University of Siena, Italy and "Bando Ricerca COVID-19 Toscana" project to Azienda Ospedaliero Universitaria Senese. We also thank Intesa SanPaolo for the 2020 charity fund dedicated to the project "N. B/2020/0119 Identificazione delle basi genetiche determinanti la variabilità clinica della risposta a COVID-19 nella popolazione italiana"; the Italian Ministry of University and Research for funding within the "Bando FISR 2020" in COVID-19 and the Istituto Buddista Italiano Soka Gakkai for funding the project "PAT-COVID: Host genetics and pathogenetic mechanisms of COVID-19" (ID n. 2020-2016_RIC_3).

Availability of data materials

The data are available for sharing through the COVID-19 dedicated section (<http://nigdb.cineca.it>), within the Network for Italian Genome (<http://www.nig.cineca.it>). The data and samples referenced here are housed in the GEN-COVID Patient Registry and the GEN-COVID Biobank and are available for consultation. You may contact the corresponding author, Prof. Alessandra Renieri (e-mail: alessandra.renieri@unisi.it).

Declarations

Ethics approval and consent to participate

The study (GEN-COVID) was consistent with Institutional guidelines and approved by the University Hospital (Azienda Ospedaliero-Universitaria Senese) Ethical Review Board, Siena, Italy (Prot n. 16917, dated March 16, 2020). The patients were informed of this research and agreed to it through the informed consent process.

Consent for publication

Not applicable.

Competing interests

All the authors declare no competing financial interests.

Author details

¹Medical Genetics Unit, University of Siena, Policlinico Le Scotte, Viale Bracci, 2, 53100 Siena, Italy. ²Department of Medical Biotechnologies, Med Biotech Hub and Competence Center, University of Siena, Siena, Italy. ³Department of Mathematics, University of Pavia, Pavia, Italy. ⁴DIISM-SAILAB, University of Siena, Siena, Italy. ⁵National Institute for the Infectious Diseases "L. Spallanzani", Rome, Italy. ⁶Stem Cell Transplant and Cellular Therapy Unit, University Hospital, Siena, Italy. ⁷Istituto di Tecnologie Biomediche – Consiglio Nazionale delle Ricerche, Segrate, MI, Italy. ⁸Genetica Medica, Azienda Ospedaliero-Universitaria Senese, Siena, Italy. ⁹Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.

Received: 1 June 2021 Accepted: 3 August 2021

Published online: 16 August 2021

References

- Tang N, Li D, Wang X, et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. *J Thromb Haemost*. 2020. <https://doi.org/10.1111/jth.14768>.
- Fallerini C, Daga S, Mantovani S, et al. Association of toll-like receptor 7 variants with life-threatening COVID-19 disease in males: findings from a nested case-control study. *Elife*. 2021;2(10):e67569. <https://doi.org/10.7554/eLife.67569>.
- Severe Covid-19 GWAS Group, Ellinghaus D, Degenhardt F, et al. Genome-wide Association Study of Severe Covid-19 with Respiratory Failure. *N Engl J Med*. 2020;383(16):1522–34. <https://doi.org/10.1056/NEJMoa2020283>.
- Baldassarri M, Picchiotti N, Fava F, et al. Shorter androgen receptor polyQ alleles protect against life-threatening COVID-19 disease in European males. *EBioMedicine*. 2021;65:103246. <https://doi.org/10.1016/j.ebiom.2021.103246>.
- Blann AD, Nadar SK, Lip GYH, et al. The adhesion molecule P-selectin and cardiovascular disease. *Eur Heart J*. 2003;24:2166–79.
- Merten M, Thiagarajan P. P-selectin in arterial thrombosis. *Z Kardiol*. 2004;93(11):855–63. <https://doi.org/10.1007/s00392-004-0146-5>.
- Bongiovanni D, Klug M, Lazareva O, et al. SARS-CoV-2 infection is associated with a pro-thrombotic platelet phenotype. *Cell Death Dis*. 2021;12(1):50. <https://doi.org/10.1038/s41419-020-03333-9>.
- Manne BK, Denorme F, Middleton EA, et al. Platelet gene expression and function in patients with COVID-19. *Blood*. 2020;136(11):1317–29. <https://doi.org/10.1182/blood.2020007214>.
- Ay C, Jungbauer LV, Kaider A, et al. P-selectin gene haplotypes modulate soluble P-selectin concentrations and contribute to the risk of venous thromboembolism. *Thromb Haemost*. 2008;99(5):899–904. <https://doi.org/10.1160/TH07-11-0672>.
- Tregouet DA, Barbaux S, Escolano S, et al. Specific haplotypes of the P-selectin gene are associated with myocardial infarction. *Hum Mol Genet*. 2002;11(17):2015–23. <https://doi.org/10.1093/hmg/11.17.2015>.
- Zhang S, Liu Y, Wang X, et al. SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19. *J Hematol Oncol*. 2020;13:120. <https://doi.org/10.1186/s13045-020-00954-7>.
- Karolczak K, Konieczna L, Kostka T, et al. Testosterone and dihydrotestosterone reduce platelet activation and reactivity in older men and women. *Aging (Albany NY)*. 2018;10(5):902–29. <https://doi.org/10.18632/aging.101438>.
- Agrati C, Bordoni V, Sacchi A, et al. Elevated P-selectin in severe Covid-19: considerations for therapeutic options. *Mediterr J Hematol Infect Dis*. 2021;13(1):e2021016. <https://doi.org/10.4084/MJHID.2021.016>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.